Keitaro Fukuda

Dr. Keitaro Fukuda

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
KFKeitaro Fukuda
Keitaro Fukuda
KOKen Okamura
Ken Okamura
RRRebecca L. Riding
Rebecca L. Riding
XFXueli Fan
Xueli Fan
KAKhashayar Afshari
Khashayar Afshari
JHJohn E. Harris
John E. Harris
The STING and absent in melanoma 2 (AIM2) pathways are activated by the presence of cytosolic DNA, and STING agonists enhance immunotherapeutic responses. Here, we show that dendritic cell (DC) expression of AIM2 within human melanoma correlates with poor prognosis and, in contrast to STING, AIM2 exerts an immunosuppressive effect within the melanoma microenvironment. Vaccination with AIM2-deficient DCs improves the efficacy of both adoptive T cell therapy and anti–PD-1 immunotherapy for “cold tumors,” which exhibit poor therapeutic responses. This effect did not depend on prolonged survival of vaccinated DCs, but on tumor-derived DNA that activates STING-dependent type I IFN secretion and subsequent production of CXCL10 to recruit CD8+ T cells. Additionally, loss of AIM2-dependent IL-1β and IL-18 processing enhanced the treatment response further by limiting the recruitment of regulatory T cells. Finally, AIM2 siRNA-treated mouse DCs in vivo and human DCs in vitro enhanced similar anti-tumor immune responses. Thus, targeting AIM2 in tumor-infiltrating DCs is a promising new treatment strategy for melanoma.

1 April 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
KFKeitaro Fukuda
Keitaro Fukuda
Melanoma is an aggressive skin cancer derived from melanocyte, which shows high response rate to cancer immunotherapy, such as immune checkpoint inhibitors (ICIs). Vitiligo is an autoimmune skin disease resulting from the destruction of melanocytes by autoreactive CD8+ T cells. Vitiligo induced by cancer immunotherapy is a favorable prognostic factor in patients with melanoma, and growing evidence supports the fact that melanocyte/melanoma-shared antigen (MSA)-specific CD8+ T cells infiltrated in the tumor (melanoma) and skin (vitiligo) microenvironment play pivotal roles in the prognosis of both diseases. Thus, cellular communications that promote MSA-specific CD8+ T cells recruitment, proliferation, and effector functions are now seen as key targets to enhance the efficacy of current therapies for both diseases. Here, we discussed recent advancements in illustrating immune signaling pathways and immune cell types that regulate migration, proliferation, and function of MSA-specific CD8+ T cells in melanoma and vitiligo; and future immunotherapeutic approaches that may enhance clinical outcomes of both diseases.

30 September 2023 in Respiratory Investigation
Verified
Journal Article
Closed access
HTHideki Terai
Hideki Terai
MIMakoto Ishii
Makoto Ishii
RTRyo Takemura
Ryo Takemura
HNHo Namkoong
Ho Namkoong
KSKyoko Shimamoto
Kyoko Shimamoto
KFKoichi Fukunaga
Koichi Fukunaga

26 October 2020 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
PDF file
RRRebecca L. Riding
Rebecca L. Riding
JRJillian M. Richmond
Jillian M. Richmond
KFKeitaro Fukuda
Keitaro Fukuda
JHJohn E. Harris
John E. Harris

1 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
KFKeitaro Fukuda
Keitaro Fukuda
CGAS and AIM2 are CDSs that are activated in the presence of cytosolic dsDNA and are expressed in various cell types, including immune and tumor cells. The recognition of tumor-derived dsDNA by CDSs in the cytosol of tumor-infiltrating dendritic cells (TIDCs) activates the innate and acquired immunity, thereby enhancing anti-tumor immune responses. STING is the downstream signaling effector of cGAS that induces type I interferon (IFN) signaling. Owing to their ability to activate TIDCs, STING agonists have been intratumorally injected in several clinical trials to enhance the anti-tumor immune response elicited by immune checkpoint antibodies. However, they have shown minimal effect, suggesting the importance of optimizing the dose and route of administration for STING agonists and deciphering other immune pathways that contribute to anti-tumor immune responses. Recent studies have revealed that AIM2 activity induces pro-tumor growth through multiple parallel pathways, including inhibition of STING-type I IFN signaling. Thus, AIM2 could be a potential molecular target for cancer immunotherapies. This review summarizes the current research on the roles of cGAS, STING, and AIM2 in immune cells and tumor cells in the tumor microenvironment and discusses the future prospects of anti-tumor treatment approaches based on these molecules.

1 December 2020 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
TFTakayuki Fusumae
Takayuki Fusumae
KFKeitaro Fukuda
Keitaro Fukuda
IHIkuko Hirai
Ikuko Hirai
YNYoshio Nakamura
Yoshio Nakamura
KTKeiji Tanese
Keiji Tanese
TFTakeru Funakoshi
Takeru Funakoshi